Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice-Reference-Cited by-同舟云学术

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice

Published:2013-02-20 Issue:2 Volume:8 Page:e56813
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Santoleri Fiorenzo,Sorice Paola,Lasala Ruggero,Rizzo Rosa Carmela,Costantini Alberto

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Safe Handling of Oral Chemotherapeutic Agents in Clinical Practice: Recommendations From an International Pharmacy Panel. J OncolPract;S Goodin;Jan,2011

2. Pharmacoeconomic analysis of adjuvant oral capecitabinevs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer;J Cassidy;April 24,2006

3. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm;SB Bartel;2007 May 1,2007

4. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl);DL Schwappach;May,2010

5. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. ActaClin Belg;V Foulon;2011 Mar-Apr,2011

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment;Hospital Pharmacy;2024-02-15

2. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia;Patient Preference and Adherence;2023-08

3. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib;Future Oncology;2023-07-21

4. Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia;Annals of Hematology;2023-07-01

5. Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration;Therapeutic Drug Monitoring;2022-12